
A
Phase 1
Phase 2
d1 d3 d7
d1 d3 d7
NES
3.6
-3.6
M11.0−enriched in monocytes (II)
M16−TLR and inflammatory signaling
M118.0−enriched in monocytes (IV)
M37.0−immune activation − generic cluster
S4−Monocyte surface signature
M165−enriched in activated dendritic cells (II)
M37.1−enriched in neutrophils (I)
M4.0−cell cycle and transcription
M4.3−myeloid cell enriched receptors and transporters
M66−TBA
S10−Resting dendritic cell surface signature
M3−regulation of signal transduction
M87−transmembrane transport (I)
M64−enriched in activated dendritic cells/monocytes
M2.1−extracellular matrix (II)
M81−enriched in myeloid cells and monocytes
M132−recruitment of neutrophils
M11.1−blood coagulation
M139−lysosomal/endosomal proteins
M111.0−viral sensing & immunity; IRF2 targets network (I)
M86.0−chemokines and inflammatory molecules in myeloid cells
M127−type I interferon response
M131−TBA
M105−TBA
M168−enriched in dendritic cells
M61.0−enriched in NK cells (II)
M7.2−enriched in NK cells (I)
S1−NK cell surface signature
M7.0−enriched in T cells (I)
M7.1−T cell activation (I)
M7.4−T cell activation (III)
S0−T cell surface signature
M7.3−T cell activation (II)
M18−T cell differentiation via ITK and PKC
M35.0−signaling in T cells (I)
M89.0−putative targets of PAX3
M4.1−cell cycle (I)
M4.2−PLK1 signaling events
M6−mitotic cell division
M47.1−enriched in B cells (II)
M47.0−enriched in B cells (I)
M47.2−enriched in B cells (III)
M156.1−plasma cells, immunoglobulins
M156.0−plasma cells & B cells, immunoglobulins
M196−platelet activation − actin binding
B
Controls - Phase 1
Controls - Phase 2
Abx-treated - Phase 1
Abx-treated - Phase 2
PC2
PC1
25
20
15
10
5
0
-5
-10
-15
-20
-25
-30
-20
-10
0
10
20
30
C
Phase 1
Phase 2
Controls
Abx-treated
Lithocholic acid
(fold change)
100
10
1
0.1
0.01
0.001
0.0001
-21
0/-21
1/-21
3/-21
7/-21
30/-21
days